FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma

BACKGROUND: Most patients with advanced pancreatic adenocarcinoma (PA) treated with FOLFIRINOX experience adverse events requiring dose reduction. We aimed to assess the association between relative dose intensity (RDI) and disease control in a European setting. METHODS: We retrospectively included...

Descripción completa

Detalles Bibliográficos
Autores principales: Vary, Antonin, Lebellec, Loïc, Di Fiore, Frédéric, Penel, Nicolas, Cheymol, Claire, Rad, Emilia, El Hajbi, Farid, Lièvre, Astrid, Edeline, Julien, Bimbai, André Michel, Le Deley, Marie-Cécile, Turpin, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287268/
https://www.ncbi.nlm.nih.gov/pubmed/34349842
http://dx.doi.org/10.1177/17588359211029825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287268/
https://www.ncbi.nlm.nih.gov/pubmed/34349842
http://dx.doi.org/10.1177/17588359211029825

Ejemplares similares